Brief: Alpha Tau Announces Completion Of Enrollment In First Us Clinical Trial Of Alpha Dart And Achievement Of First Primary Objective
Oct 25 (Reuters) - Healthcare Capital Corp HCCC.O :
* ALPHA TAU ANNOUNCES COMPLETION OF ENROLLMENT IN FIRST US
CLINICAL TRIAL OF ALPHA DART™ AND ACHIEVEMENT OF FIRST PRIMARY
OBJECTIVE
* ALPHA TAU MEDICAL - TRIAL HAS MET ITS FIRST PRIMARY
OBJECTIVE,
IN DEMONSTRATING FEASIBILITY OF SUCCESSFUL DELIVERY OF ALPHA
DART
Source text for Eikon: ID:nPn20pBW5a
Further company coverage: HCCC.O
Recent news on Alpha Tau Medical
See all newsBrief: Alpha Tau Completes Patient Enrollment In Its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal Of FDA Approval Of Alpha Dart® To Treat Recurrent Cutaneous Squamous Cell Carcinoma
Brief: Alpha Tau Announces 100% Local Disease Control Rate And Favorable Safety Profile Observed In Alpha Dart® Pancreatic Cancer Trials Presented At Ddw 2026
Brief: Alpha Tau Medical Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Alpha Tau Announces First-Ever Oral Presentation Of Alpha Dart® Pancreatic Cancer Data At Digestive Disease Week (Ddw) 2026
Brief: Alpha Tau Medical Receives Japanese Marketing Approval For Alpha Dart In Head And Neck Cancer